Please login to the form below

Not currently logged in
Email:
Password:

Healthcare Collaboration Award

  • Full Results
    • Winner

      Epidermal Growth Factor Receptor (EGFR) mutation testing network in advanced non-small cell lung Cancer (NSCLC)

      AstraZeneca UK in association with Creative Lynx, iS Health and Munro & Forster


      Highly commended

      Can You Feel My Pain? Partnership

      Pfizer

      ChloraPrep

      Carefusion in association with Seven Stones


      Finalists

      Joint Working?

      Arthritis and Musculoskeletal Alliance, Chugai & Roche, supported by MHP Health Mandate

      Paper to Patient

      GlaxoSmithKline in association with eBee


Winner

Epidermal Growth Factor Receptor (EGFR) mutation testing network in advanced non-small cell lung Cancer (NSCLC)

AstraZeneca UK in association with Creative Lynx, iS Health and Munro & Forster


Summary of work

Winner: AstraZeneca UK in association with Creative Lynx, iS Health and Munro & Forster

Clinical data indicates that approximately 70 per cent of patients with advanced non-small cell lung cancer (NSCLC), whose tumours are epidermal growth factor receptor (EGFR) mutation positive, respond to first-line treatment with gefitinib, with improvements in symptoms and quality of life, compared with doublet chemotherapy.

Despite the clinical benefits of gefitinib, AstraZeneca UK recognised that HCPs faced several constraints preventing them from prescribing gefitinib. ln 2009, there was no requirement to test for the EGFR mutation in advanced NSCLC, therefore these tests were not routinely carried out and no network of expertise existed. Without the mechanism to test for EGFR mutations, no patient could be given gefitinib, as it is licensed only for this subgroup.

Recognising that the lack of access to EGFR testing was a barrier, AstraZeneca UK worked in partnership with NHS stakeholders across oncology, pathology, genetics and chest medicine to establish a network of EGFR genetic testing centres to drive increased, high-quality testing with rapid turnaround times.

AstraZeneca UK engaged with leading oncologists, pathologists, geneticists and chest physicians to ensure that EGFR testing was conducted optimally to meet the needs of HCPs. A national steering committee was set up to review data from the laboratories, drive best practice and help develop educational materials for the wider healthcare professional community to increase understanding of the value of EGFR testing and overcome barriers to make testing available.

Astrazeneca UK's partnership with the NHS has led to a sea change in the delivery of personalised medicine in lung cancer. A total of 18 laboratories joined the national testing service; 219 tests were carried out in 2009 rising to 5,435 in 2010. The positive recommendation of gefitinib by NICE in July 2010 also recommended a 'test all' approach to EGFR mutation-positive testing for patients.

Judges comments

“This partnership is an excellent example of collaboration, which employed a multi-faceted marketing approach that included a variety of tactics to influence testing uptake by oncologists. This is a very good piece of work with clear results and significant behavioural change over a sustained period of time.”

Stakeholder comments

"This programme certainly supported healthcare professionals in the drive to improve the care of people with advanced NSCLC, helping bring together all the different stakeholders involved in EGFR testing, particularly pathologists and laboratory scientists, to adopt best practice and therefore drive high-quality EGFR testing and subsequently improve patient outcomes."
Professor of Pulmonary Pathology, Aberdeen University Medical School and Consultant Pathologist, Aberdeen Royal lnfirmary

"This programme has been a win–win for healthcare professionals. It has provided pathologists and geneticists with the support and infrastructure to carry out testing and given oncologists the means to tailor treatment to the needs of their individual patient helping to improve outcomes. It has enabled the NHS to deliver improvements in the patient pathway and ensure the treatment that is prescribed is cost-effective and most likely to benefit the patient. This initiative has delivered a genuine sea change in the delivery of personalised medicine in lung cancer. In addition, this service has generated data on the epidemiology of EGFR gene mutations in the UK that will prove valuable for research and for driving further improvements in the treatment of patients with NSCLC.”
Lung Cancer National Clinical Lead

Highly commended


Highly commended

ChloraPrep - Carefusion in association with Seven Stones


Finalists

Joint Working? - Arthritis and Musculoskeletal Alliance, Chugai & Roche, supported by MHP Health Mandate

Paper to Patient - GlaxoSmithKline in association with eBee